Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevenar proof-of-pharmacology study for anti-oxidized LDL antibodies
NL-OMON43410Phase 2Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pneumococcal 7-valent conjugate vaccine in atherosclerosis and hypercholesterolemia, sponsored by Centre for Human Drug Research. Primary endpoints: Total immunoglobulin titers, Anti-oxidized LDL antibody titers and 9 more. Started Apr 2016; status: active, not recruiting.
02
Drugs
pneumococcal 7-valent conjugate vaccine
03
Conditions
atherosclerosishypercholesterolemia
Beyond the preview
Go deeper on NL-OMON43410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43410.